Injectable foam prototype could seal deep wounds and help prevent amputations

AleSac, a startup based on research from Technical University of Denmark (DTU), is developing a prototype injectable foam that could revolutionize the treatment of deep wounds and potentially prevent amputations. The silicone compound, when injected directly into the wound, expands into a soft foam that not only removes harmful wound fluid but also creates ideal conditions for managing complex injuries.

The technology behind the wound foam has the potential to be especially beneficial in treating severe traumatic wounds, including blast injuries and other complex injuries where rapid treatment can be crucial for saving tissue and avoiding amputations. Furthermore, the technology could be valuable in crisis areas where patients may not have immediate access to advanced hospital treatment, making infection management crucial for the healing process.

Traditional wound care methods often involve flat adhesive bandages and dressings, which are not well-suited for deep, complex wounds with irregular shapes. AleSac's solution addresses this challenge by using a physical prototype that specifically fits the wound's geometry, creating better conditions for managing complex injuries.

In laboratory tests, AleSac's antibacterial foam has proven effective against multidrug-resistant bacteria within 120 minutes. However, while the startup has shown promising results, the clinical benefits, including reduced amputations or mortality rates, remain to be established.

AleSac has been accepted into the U.S. medtech accelerator program BioLab CATALYST, a significant milestone that will provide the company with access to unique regulatory expertise and a strong international network of investors. This support will help AleSac bring this innovative wound treatment to patients in the U.S. market.